BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cowan KJ. Implementing fit-for-purpose biomarker assay approaches: a bioanalytical perspective. Bioanalysis 2016;8:1221-3. [DOI: 10.4155/bio-2016-0070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Mehta D, Purushothama S, Stevenson L. Parallelism: the foundation of biomarker assay development and validation. Bioanalysis 2018;10:897-9. [DOI: 10.4155/bio-2017-0284] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tu J, Bennett P. Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons. Bioanalysis 2017;9:1107-22. [DOI: 10.4155/bio-2017-0084] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
3 Hays A, Amaravadi L, Fernandez-Metzler C, King L, Mathews J, Ni Y, Quadrini K, Tinder C, Vazvaei F, Zeng J. Is Incurred Sample Reanalysis (ISR) Applicable in Biomarker Assays? AAPS J 2022;24:65. [PMID: 35511303 DOI: 10.1208/s12248-022-00708-y] [Reference Citation Analysis]
4 Ng AWR, Narayanan K. An antibody binding-based fluorescent assay for the rapid quantification of globotriaosylceramide levels in human Fabry cells. Anal Biochem 2021;628:114287. [PMID: 34119486 DOI: 10.1016/j.ab.2021.114287] [Reference Citation Analysis]